- Home
- DRMA vs WLGS Comparison
DRMA vs WLGS Comparison
Compare DRMA & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- WLGS
- Stock Information
- Founded
- DRMA 2014
- WLGS 1981
- Country
- DRMA United States
- WLGS Hong Kong
- Employees
- DRMA N/A
- WLGS N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- WLGS Engineering & Construction
- Sector
- DRMA Health Care
- WLGS Consumer Discretionary
- Exchange
- DRMA Nasdaq
- WLGS Nasdaq
- Market Cap
- DRMA 4.5M
- WLGS 4.4M
- IPO Year
- DRMA 2021
- WLGS 2023
- Fundamental
- Price
- DRMA $0.71
- WLGS $0.06
- Analyst Decision
- DRMA Strong Buy
- WLGS
- Analyst Count
- DRMA 1
- WLGS 0
- Target Price
- DRMA $3.00
- WLGS N/A
- AVG Volume (30 Days)
- DRMA 118.5K
- WLGS 67.3M
- Earning Date
- DRMA 08-06-2025
- WLGS 08-14-2025
- Dividend Yield
- DRMA N/A
- WLGS N/A
- EPS Growth
- DRMA N/A
- WLGS N/A
- EPS
- DRMA N/A
- WLGS N/A
- Revenue
- DRMA N/A
- WLGS $3,951,649.00
- Revenue This Year
- DRMA N/A
- WLGS N/A
- Revenue Next Year
- DRMA N/A
- WLGS N/A
- P/E Ratio
- DRMA N/A
- WLGS N/A
- Revenue Growth
- DRMA N/A
- WLGS N/A
- 52 Week Low
- DRMA $0.57
- WLGS $0.03
- 52 Week High
- DRMA $5.00
- WLGS $9.66
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- WLGS 35.41
- Support Level
- DRMA $0.61
- WLGS $0.04
- Resistance Level
- DRMA $0.74
- WLGS $0.05
- Average True Range (ATR)
- DRMA 0.06
- WLGS 0.01
- MACD
- DRMA 0.01
- WLGS 0.01
- Stochastic Oscillator
- DRMA 67.43
- WLGS 60.45
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.